Duoneb Articles

Merck KGaA 2nd-qtr as expected

1 August 2005

Families USA slams US seniors' Rx prices; PhRMA challenges earlier cost claims

7 June 2004

Merck KGaA erases debt with sale of VWR; reports organic growth of 7% for 2003

23 February 2004

BI hit by costs and currencies in first half

11 August 2003

US price rises for most-prescribed drugs to seniors are well ahead of

21 July 2003

Profits set to fall at Boehringer Ingelheim ahead of key product launches

14 April 2003

Strong 4th-quarter operating results at Merck KGaA on flat sales

24 February 2003

Multiple-inflation rate price rises claimed for US seniors' most-used Rx drugs

8 July 2002

Boeh Ingelheim reaping benefits of being family-run with steady growth

15 April 2002

Boehringer Ingelheim's Spiriva approved in first market, the Netherlands

25 October 2001

New Spiriva data reinforce profile of potential COPD blockbuster

26 September 2001

Global pulmonary drug delivery market forecasts

24 September 2001

Germany's Boehringer Ingelheim looking to Spiriva as growth driver

3 May 2001

Pfizer to co-market Boehringer Ingelheim COPD drug with blockbuster

12 April 2001

Boeh Ingelheim restates independence strategy driven by innovative research

5 May 2000

Combivent Attack: Boeh Ingelheim Replies

5 November 1998

Poor Rxing "Costs UK NHS L100 Mill/Year In England"

28 October 1998

Sales Well Up And Solid Growth At Boehringer Ingelheim

26 August 1997

Boeh Ingelheim To Focus On Alliances

20 May 1996

UK Prescription Medicine Code Of Practice Review

4 December 1995

USA Lags Foreign Approvals, PhRMA Demonstrates

16 October 1995

Boeh Ing launches Combivent UDV

3 July 1995

B-I Receives Two Approval Recommendations In USA

25 July 1994

BOEHRINGER INGELHEIM RECEIVES NOT APPROVABLE LETTER

14 March 1994

BOEHRINGER INGELHEIM GETS GO-AHEAD FOR US TRIALS

19 July 1993

Showing 1-25 of 25 articles

Go to beginningPrevious
  • 1
NextGo to end